<DOC>
	<DOCNO>NCT00572650</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics vildagliptin ( LAF237 ) metabolites patient mild renal impairment compare sex , age weigh base healthy volunteer counterpart .</brief_summary>
	<brief_title>Pharmacokinetic Study LAF237 Its Metabolites Mild Renal Impaired Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Age 18 75 year age ( inclusive ) . Male , nonfertile female female childbearing potential use medically approve birth control method . Body mass index ( BMI ) ≤42 kg/m2 ( inclusive ) Screening . Able provide write informed consent prior study participation . Able communicate well investigator comply requirement study . For renal insufficient patient Patients must stable renal disease without evidence renal progressive disease If patient diabetic , must treat standard antidiabetic therapy andmust agree continue antidiabetic therapy throughout duration study . If patient diabetic , must stable dose standard antidiabetic therapy diet exercise regimen past 4 week prior Screening . For healthy subject No current significant medical condition determine history physical . A serum creatinine calculate CrCl &gt; 80 ml/min . Matched renal impaired patient ( Group A ) undergoing study age ( ±5 year ) , sex weight ( ±10 % BMI ) . Subjects meet follow criterion screen baseline evaluation exclude entry continuation study : Pregnant lactate female . A history certain disorder specify protocol . Subjects enrol LAF237 ( vildagliptin ) study DPP4 inhibitor study six month prior Baseline . History renal transplant time past immunosuppressant therapy . Acute infection may affect blood glucose control within 4 week prior Screening concurrent medical condition may interfere interpretation efficacy safety data study . Certain electrocardiogram ( ECG ) abnormality : Malignancy include leukemia lymphoma ( include basal cell skin cancer ) within last 5 year . Liver disease cirrhosis positive hepatitis B C. Any alcohol relate hepatic disease . Patients undergo method dialysis ( hemodialysis peritoneal dialysis ) Concurrent medical condition may interfere interpretation safety tolerability data study . Use certain medication specify protocol . Laboratory abnormality define protocol History active substance abuse ( include alcohol ) within past 2 year . Smokers define subject report heavy cigarette use ( i.e. , 10 cigarette per day ) . Urine cotinine also measure record Screening Baseline . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Type-2 diabetes , DPP-4 inhibitor , vildagliptin</keyword>
</DOC>